公开(公告)号：US20190275149A1

公开(公告)日：2019-09-12

申请号：US16248402

申请日：2019-01-15

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K47/68

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US10344050B2

公开(公告)日：2019-07-09

申请号：US14353962

申请日：2012-10-26

Applicant: GENMAB A/S

Inventor： Michael Gramer ,  Amitava Kundu ,  Ewald T. J. Van Den Bremer ,  Muriel Van Kampen ,  Patrick Priem ,  Aran Frank Labrijn ,  Joyce I. Meesters ,  Joost J. Neijssen ,  Janine Schuurman ,  Paul Parren ,  Patrick Van Berkel ,  Werner L. Vos ,  Arnout Gerritsen

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/46 ,  C07K1/113

Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.

公开(公告)号：US10201607B2

公开(公告)日：2019-02-12

申请号：US15938961

申请日：2018-03-28

Applicant: GENMAB A/S

Inventor： Esther Breij ,  David Satijn ,  Edward Norbert Van Den Brink ,  Dennis Verzijl ,  Rob N. De Jong ,  Paul Parren ,  Riemke Van Dijkhuizen Radersma

IPC: A61K39/00 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20190030178A1

公开(公告)日：2019-01-31

申请号：US15758520

申请日：2016-09-09

Applicant: GENMAB A/S

Inventor： Steen LISBY ,  Nancy Cherry WHITING

IPC: A61K47/68 ,  A61K38/07 ,  C07K16/36

Abstract: Anti-TF antibody drug conjugate and pharmaceutical compositions comprising the antibody drug-conjugate for use in the treatment of a solid cancer comprising administering to a subject a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an anti-TF antibody drug conjugate once a week for three consecutive weeks followed by a one week resting period without any administration of anti-TF ADC so that each cycle time is 28 days including the resting period.

公开(公告)号：US20190022243A1

公开(公告)日：2019-01-24

申请号：US16069395

申请日：2017-01-13

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00

Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.

公开(公告)号：US20180214549A1

公开(公告)日：2018-08-02

申请号：US15938961

申请日：2018-03-28

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K47/6801 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61K2039/505 ,  A61K2121/00 ,  C07K16/2863 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20170362319A1

公开(公告)日：2017-12-21

申请号：US15414254

申请日：2017-01-24

Applicant: GENMAB A/S

Inventor： Catharina Emanuele GERARDA HAVENITH ,  Tom VINK ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/28 ,  G01N33/566

CPC classification number: C07K16/2812 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/76 ,  G01N33/566 ,  G01N2333/70535

Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.

公开(公告)号：US20170320962A1

公开(公告)日：2017-11-09

申请号：US15491378

申请日：2017-04-19

Applicant: GENMAB A/S

Inventor： Joost J. NEIJSSEN ,  Bart DE GOEIJ ,  Edward Norbert VAN DEN BRINK ,  Aran Frank LABRIJN ,  Rene HOET ,  Janine SCHUURMAN ,  Paul PARREN ,  Jan VAN DE WINKEL

IPC: C07K16/30 ,  A61K45/06 ,  C07K16/40 ,  A61K39/395 ,  G01N33/574 ,  C07K16/28 ,  A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20170233497A1

公开(公告)日：2017-08-17

申请号：US15414122

申请日：2017-01-24

Applicant: GENMAB A/S

Inventor： Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Ewald T. J. VAN DEN BREMER ,  Joost J. NEIJSSEN ,  Patrick VAN BERKEL ,  Bart DE GOEIJ ,  Tom VINK ,  Jan VAN DE WINKEL ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/46 ,  C07K16/32 ,  C07K16/28

CPC classification number: C07K16/468 ,  A61K2039/505 ,  C07K16/1063 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6854

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins

公开(公告)号：US09598493B2

公开(公告)日：2017-03-21

申请号：US14592558

申请日：2015-01-08

Applicant: GENMAB A/S

Inventor： Janine Schuurman ,  Catharina Emanuele Gerarda Havenith ,  Paul Parren ,  Jan G. J. Van De Winkel ,  Denise Leah Williams ,  Jørgen Petersen ,  Ole Baadsgaard

IPC: C07K16/28 ,  G01N33/68 ,  A61K39/395 ,  A61K45/06 ,  A61N5/06 ,  C07K16/42 ,  C07K16/46 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/062 ,  C07K16/4258 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/56966 ,  G01N33/57492 ,  G01N33/6854 ,  G01N33/6869 ,  G01N2333/70596 ,  G01N2333/715 ,  G01N2333/7155

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.